Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the efficacy and safety of 32 mg naltrexone sustained-release (SR)/360 mg bupropion SR (NB) in overweight/obese individuals with type 2 diabetes with or without background oral antidiabetes drugs. RESEARCH DESIGN AND METHODS: This was a 56-week, double-blind, placebo-controlled study in which 505 patients received standardized lifestyle intervention and were randomized 2:1 to NB or placebo. Coprimary end points were percent weight change and achievement of ≥5% weight loss. Secondary end points included achievement of HbA1c <7% (53 mmol/mol), achievement of weight loss ≥10%, and change in HbA1c, waist circumference, fasting blood glucose, and lipids. RESULTS: In the modified intent-to-treat population (54% female, 80% Caucasian, and mean age 54 years, weight 106 kg, BMI 37 kg/m2, and HbA1c 8.0% [64 mmol/mol]), NB resulted in significantly greater weight reduction (−5.0 vs. −1.8%; P < 0.001) and proportion of patients achieving ≥5% weight loss (44.5 vs. 18.9%, P < 0.001) compared with placebo. NB also resulted in significantly greater HbA1c reduction (−0.6 vs. −0.1% [6.6 vs. 1.1 mmol/mol]; P < 0.001), percent of patients achieving HbA1c <7% (53 mmol/mol) (44.1 vs. 26.3%; P < 0.001), and improvement in triglycerides and HDL cholesterol compared with placebo. NB was associated with higher incidence of nausea (42.3 vs. 7.1%), constipation (17.7 vs. 7.1%), and vomiting (18.3 vs. 3.6%). No difference was observed between groups in the incidence of depression, suicidal ideation, or hypoglycemia. CONCLUSIONS: NB therapy in overweight/obese patients with type 2 diabetes induced weight loss, which was associated with improvements in glycemic control and select cardiovascular risk factors and was generally well tolerated with a safety profile similar to that in patients without diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Even so, in subanalyses, persons losing more than 10% of weight at 1 year experienced a 21% reduction in the composite CVD outcome.734”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [734]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Similar attenuation in weight loss in patients with vs without type 2 diabetes has been observed with other AOM, including orlistat,(44) naltrexone-bupropion,(45) and liraglutide 3.0 mg,(46) as well as with some behavioral interventions.(47, 48)”
From Semaglutide for the treatment of obesity (2023) · cites this paper as [45]
The cited source says what the claim attributes to it.
In the citing paper
“In COR-Diabetes, naltrexone/bupropion yielded − 5% weight loss and − 0.6% HbA1c reductions [35].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [35]
In the citing paper
“Naltrexone plus bupropion extended-release reduces weight on average by ≈7% (≈5% placebo-subtracted) [51][52][53][54] and also more than either agent administered alone.55”
From Approach to Obesity Treatment in Primary Care: A Review (2024) · cites this paper as [52]
In the citing paper
“Other AOMs have yielded comparably smaller weight losses in patients with versus without type 2 diabetes [58].”
From The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities (2023) · cites this paper as [58]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Prevalence of Obesity and Trends in the Distribution of Body Mass Index Among US Adults, 1999-2010
Flegal, K. M., Carroll, M. D., Kit, B. K., & Ogden, C. L. (2012) · JAMA · doi:10.1001/jama.2012.39 · Cited by 5,385
Abdominal obesity and metabolic syndrome
Després, J.-P., & Lemieux, I. (2006) · Nature · doi:10.1038/nature05488 · Cited by 4,354
Christiane, Druml, Wolzt, & Pleiner (2001) · Acta Scientiarum Naturalium Universitatis Sunyatseni · Cited by 3,419
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
Central nervous system control of food intake and body weight
Morton, G. J., Cummings, D. E., Baskin, D. G., Barsh, G. S., & Schwartz, M. W. (2006) · Nature · doi:10.1038/nature05026 · Cited by 2,503 · cited 2×
“Furthermore, naltrexone and bupropion therapy are believed to influence the mesolimbic dopaminergic reward system,which canmodulate reward behaviors such as food intake (14,15).”
Background
Research works printed but not linked: 1
- Sinnayah, 2007, Bupropion and naltrexone interact synergistically to decrease food intake in mice, Obesity (Silver Spring), 15, A179
Cited by
Items 201–300 of 500
Current and Emerging Treatment Options in Diabetes Care
Clemmensen, C., Müller, T. D., Finan, B., Tschöp, M. H., & DiMarchi, R. D. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_7 · Cited by 23
Diabetes mellitus risk for 102 drugs and drug combinations used in patients with bipolar disorder
Nestsiarovich, A., Kerner, B., Mazurie, A., Cannon, D. C., Hurwitz, N. G., Zhu, Y., Nelson, S. J., Oprea, T. I., Crisanti, A. S., Tohen, M. F., et al. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.104511 · Cited by 25
“With regard to bupropion, the data support its weight-neutral properties (Serretti and Mandelli, 2010) and beneficial role in the management of obesity, glucose, and lipid metabolism disturbances (Anderson et al., 2002; Hollander et al., 2013).”
BackgroundPharmacotherapy for obesity in individuals with type 2 diabetes
Chukir, T., Shukla, A. P., Saunders, K. H., & Aronne, L. J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1428558 · Cited by 22
Current and Emerging Pharmacotherapies for Weight Management in Prediabetes and Diabetes
Lau, D. C. W., & Teoh, H. (2015) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2015.10.001 · Cited by 26
Weight-centric treatment of depression and chronic pain
Ghusn, W., Bouchard, C., Frye, M. A., & Acosta, A. J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100025 · Cited by 24
“The weight loss associated with Contrave ranged between 5.9% and 11.5% at 56 weeks in the Contrave Obesity Research Clinical Trials (4,536 patients) [86 – 89].”
BackgroundInfluentialSmith, I., Hardy, E., Mitchell, S., & Batson, S. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s392952 · Cited by 39
A Comparison of New Pharmacological Agents for the Treatment of Obesity
Nuffer, W. A., Trujillo, J. M., & Megyeri, J. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016634351 · Cited by 24
Gill, L. A., & Mackey, S. (2021) · Journal of Women s Health · doi:10.1089/jwh.2020.8683 · Cited by 22
From Pharmacology to Physiology: Endocrine Functions of μ-Opioid Receptor Networks
Jaschke, N., Pählig, S., Pan, Y., Hofbauer, L. C., Göbel, A., & Rachner, T. D. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2021.02.004 · Cited by 24
Antiobesity drug therapy: An individualized and comprehensive approach
Mauer, Y., Parker, M., & Kashyap, S. R. (2021) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.20080 · Cited by 26
Managing weight and glycaemic targets in people with type 2 diabetes—How far have we come?
Blüher, M., Ceriello, A., Davies, M. J., Rodbard, H. W., Sattar, N. A., Schnell, O., Tonchevska, E., & Giorgino, F. (2022) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.330 · Cited by 22
Pharmacological profile of once-weekly injectable semaglutide for chronic weight management
Lau, D. C. W., Batterham, R. L., & le Roux, C. W. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2070473 · Cited by 27
“0 mg [50], orlistat (three times daily oral administration) [56], phentermine–topiramate (once-daily oral administration) [57], and naltrexone–bupropion (twice-daily oral administration) [58].”
Olszanecka‐Glinianowicz, M., Mazur, A., Chudek, J. T., Kos‐Kudła, B., Markuszewski, L., Dudek, D., Major, P., Małczak, P., Tarnowski, W., Jaworski, P., et al. (2023) · Nutrients · doi:10.3390/nu15071641 · Cited by 30
The role of anti-obesity medication in prevention of diabetes and its complications
Oh, T. J. (2019) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes.2019.28.3.158 · Cited by 19
Nie, X., Mu, G., Yang, S., Ye, Z., Wang, M., Wang, D., Ma, J., Guo, Y., Wang, B., Dai, W., et al. (2021) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2021.126548 · Cited by 18
Pharmacotherapeutic management of comorbid polycystic ovary syndrome and diabetes
Ortiz-Flores, A. E., Luque‐Ramírez, M., & Escobar-Morreale, H. F. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1528231 · Cited by 23
Kolotkin, R. L., Chen, S., Klassen, P., Gilder, K. M., & Greenway, F. L. (2015) · Clinical Obesity · doi:10.1111/cob.12108 · Cited by 23
Self-citationExamining the evidence for weight management in individuals with type 2 diabetes
Garvey, W. T., Umpierrez, G. E., Dunn, J. P., Kwan, A. Y. M., Varnado, O. J., Konig, M., & Levine, J. A. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14764 · Cited by 18
“001) compared with placebo.(58) A significantly greater proportion of participants treated with NB achieved WL of 5% or higher (44.”
BackgroundResultAntiobesity Pharmacotherapy for Patients with Type 2 Diabetes: Focus on Long-Term Management
Jeon, W. S., & Park, C.-Y. (2014) · Endocrinology and Metabolism · doi:10.3803/enm.2014.29.4.410 · Cited by 18
Safety and efficacy of naltrexone for weight loss in adult patients – a systematic review
Kułak-Bejda, A., Bejda, G., & Waszkiewicz, N. (2020) · Archives of Medical Science · doi:10.5114/aoms.2020.96908 · Cited by 24
Could Online Education Replace Face-to-Face Education in Diabetes? A Systematic Review
Alonso-Carril, N., Rodriguez-Rodríguez, S., Quirós, C., Berrocal, B., Amor, A. J., Barahona, M. J., Martínez, D., Ferré, C., & Perea, V. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01595-6 · Cited by 21
Drugs to treat obesity: do they work?
Kim, S. (2016) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2015-133388 · Cited by 20
Behary, P., Cegla, J., Tan, T., & Bloom, S. R. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1048181 · Cited by 20
Wen, Z. G., Zhang, Q. Q., Zhang, L. L., Shen, M. F., Huang, Y., & Zhao, L. H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.964495 · Cited by 22
“, 2010) have shown that it can effectively reduce body weight and HbA1c by inhibiting neuronal reuptake of dopamine and norepinephrine (Polak et al., 2006; Hollander et al., 2013).”
BackgroundNext Generation of Weight Management Medications: Implications for Diabetes and CVD Risk
Wharton, S., & Serodio, K. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0590-z · Cited by 19
Kumar, R. B., & Aronne, L. J. (2016) · Techniques in Gastrointestinal Endoscopy · doi:10.1016/j.tgie.2016.11.003 · Cited by 19
Cope, R. J., Fischetti, B., Kavanagh, R., Lepa, T. M., & Sorbera, M. A. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2342 · Cited by 17
Kim, K. K. (2019) · Korean Journal of Family Medicine · doi:10.4082/kjfm.19.0013 · Cited by 20
Incorporating Weight Loss Medications Into Hepatology Practice for Nonalcoholic Steatohepatitis
Do, A., Kuszewski, E. J., Langberg, K. A., & Mehal, W. Z. (2019) · Hepatology · doi:10.1002/hep.30658 · Cited by 20
High-Dose Once-Weekly Semaglutide: A New Option for Obesity Management
Bradley, C. L., McMillin, S. M., Hwang, A. Y., & Sherrill, C. H. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280211053867 · Cited by 16
Bellanca, C. M., Augello, E., Benedetto, G. D., Burgaletto, C., Cantone, A. F., Cantarella, G., Bernardini, R., Polosa, R., & the DiaSmokeFree Working Group (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1406860 · Cited by 17
Long-Term Efficacy and Safety of Nutritional and Pharmacological Strategies for Obesity
Barrea, L., Boschetti, M., Gangitano, E., Guglielmi, V., Verde, L., & Muscogiuri, G. (2025) · Current Obesity Reports · doi:10.1007/s13679-024-00602-y · Cited by 21
Quantifying energy intake changes during obesity pharmacotherapy
Göbel, B., Sanghvi, A., & Hall, K. D. (2014) · Obesity · doi:10.1002/oby.20813 · Cited by 17
“We found 15 studies matching our search criteria investigating 14 different drugs or drug combinations (10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24).”
BackgroundBupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity
Ali, K. F., Shukla, A. P., & Aronne, L. J. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1100072 · Cited by 18
“[42,45] In the COR-D trial, statistical significance was only observed in TG levels (−11.2% vs. −0.8”
BackgroundMethodInfluentialThe Role of the Melanocortin System in Drug and Alcohol Abuse
Navarro, M. (2017) · International review of neurobiology · doi:10.1016/bs.irn.2017.06.009 · Cited by 18
The Challenge of Obesity Treatment: A Review of Approved Drugs and New Therapeutic Targets
Bonamichi, B. D. S. F., Parente, E. B., dos Santos, R. B., Beltzhoover, R., Lee, J., & Salles, J. E. N. (2018) · Journal of Obesity & Eating Disorders · doi:10.21767/2471-8203.100034 · Cited by 20
“The Contrave Obesity Research (COR) trials were four, randomized, double-blind, placebo-controlled trials (COR-I, COR-II, COR-BMOD, and COR-Diabetes) designed for dose optimization and for the long-term analysis of the effectiveness and safety of extended-release Naltrexone– Bupropion [27-30].”
Hong, K. M., Herrmann, K., Dybala, C., Halseth, A. E., Lam, H., & Foreyt, J. P. (2016) · Clinical Obesity · doi:10.1111/cob.12157 · Cited by 18
“The COR-Diabetes study (10) was not included in the analysis because nearly 80% of study subjects were concomitantly taking metformin, a medication for diabetes that is itself associated with nausea (12).”
BackgroundAn update on naltrexone/bupropion extended-release in the treatment of obesity
Saunders, K. H., Igel, L. I., & Aronne, L. J. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1244527 · Cited by 19
Oxytocin as a potential pharmacological tool to combat obesity
Olszewski, P. K., Noble, E. E., Paiva, L., Ueta, Y., & Blevins, J. E. (2022) · Journal of Neuroendocrinology · doi:10.1111/jne.13106 · Cited by 19
Pharmacologic Weight Management in the Era of Adolescent Obesity
Raman, V. S., Gupta, A., Ashraf, A. P., Breidbart, E., Gourgari, E., Kamboj, M. K., Kohn, B., Krishnan, S., Lahoti, A., Matlock, K. A., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac418 · Cited by 15
Self-citationSaleem, M., Fareed, M. M., Saani, M. S. A., & Shityakov, S. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2222837 · Cited by 20
“However, these medications are not available in Europe (Hollander et al., 2013).”
BackgroundPrescription Medications for the Treatment of Obesity
Preiato, V. L., Serban, D. E., Pasquali, R., & Pagotto, U. (2014) · Springer eBooks · doi:10.1007/978-3-319-09045-0_23 · Cited by 15
“1 % for placebo [27].”
BackgroundBensignor, M. O., Kelly, A. S., & Arslanian, S. A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1043650 · Cited by 16
“, 2013 (5) 56-week, double-blind, RCT; 2:1 randomization to NB or placebo.”
BackgroundInfluentialWeight Loss Therapies and Hypertension Benefits
Katsi, V. K., Manta, E., Fragoulis, C., & Tsioufis, K. P. (2024) · Biomedicines · doi:10.3390/biomedicines12102293 · Cited by 17
Developmental Considerations for the Use of Naltrexone in Children and Adolescents
Stancil, S. L., Abdel‐Rahman, S. M., & Wagner, J. (2021) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-26.7.675 · Cited by 23
Willame, H., Wacquier, B., Point, C., Dosogne, M., Faker, M. A., Loas, G., & Hein, M. (2022) · Journal of Clinical Hypertension · doi:10.1111/jch.14411 · Cited by 14
Schwartz, S. S., & Herman, M. E. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1043182 · Cited by 14
Garvey, W. T. (2016) · Diabetes Care · doi:10.2337/dc16-1611 · Cited by 14
Quiñones, M., Fernø, J., Diéguez, C., Nogueiras, R., & Al–Massadi, O. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1583642 · Cited by 14
“efficient in the reduction of feeding and body weight in obese humans [27,28].”
BackgroundMuzurović, E. M., Dragnić, S., Medenica, S., Smolović, B., Bulajić, P., & Mikhailidis, D. P. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107619 · Cited by 17
▼Naltrexone/bupropion for obesity
(2017) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2017.11.0550 · Cited by 20
Role of Bupropion Plus Naltrexone for the Management of Obesity
Booth, K., & Clements, J. N. (2016) · Journal of Pharmacy Technology · doi:10.1177/8755122515624220 · Cited by 13
“COR-Diabetes trial is the only study conducted among participants with diabetes (n = 505).(23) In this trial, there were similarities in the patient population, except the CORDiabetes trial had older patients (63 years) compared to the COR-BMOD, COR-I, and COR-II trials.”
BackgroundMethodResultInfluentialKhani, M., Afsahi, R., Nasab, A. E., Bi’aragh, S. H., Rasouli, K., Ahangar, M. H., Soltani, A., & Pourahmad, R. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01925-z · Cited by 23
Anti-obesity weight loss medications: Short-term and long-term use
Jeong, D., & Priefer, R. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120825 · Cited by 19
Beyond lifestyle interventions: exploring the potential of anti‐obesity medications in the UK
Wilding, J. P. H. (2018) · Clinical Obesity · doi:10.1111/cob.12248 · Cited by 13
Pharmacotherapy of obesity in complex diseases
Pulipati, V. P., & Pannain, S. (2021) · Clinical Obesity · doi:10.1111/cob.12497 · Cited by 15
“05).(19) The COR-I and COR-II trials excluded patients with DM and do not report data on prediabetes.”
BackgroundPharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity
Gudzune, K. A., Apovian, C. M., Aroda, V. R., Aronne, L. J., Balapattabi, K., Bennett, A. K., ChallaSivaKanaka, S., ElSayed, N. A., Fitch, A., Fitzpatrick, S. L., et al. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci25-0008 · Cited by 26
Obesity–An Update on the Basic Pathophysiology and Review of Recent Therapeutic Advances
Gjermeni, E., Kirstein, A., Kolbig, F., Kirchhof, M., Bundalian, L., Katzmann, J. L., Laufs, U., Blüher, M., Garten, A., & Duc, D. L. (2021) · Biomolecules · doi:10.3390/biom11101426 · Cited by 155
Can we win the war on obesity with pharmacotherapy?
Gotthardt, J. D., & Bello, N. T. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1232164 · Cited by 12
“4%) included constipation, upper abdominal pain, and migraine [53,55,56,58].”
BackgroundCurrent and emerging pharmacotherapies for obesity in Australia
HOCKING, S. L., Dear, A. E., & Cowley, M. A. (2017) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2017.07.002 · Cited by 14
Pharmacological therapies to address obesity in type 1 diabetes
Casu, A., Bilal, A., & Pratley, R. E. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000555 · Cited by 16
Wharton, S., Yin, P., Burrows, M., Gould, E. M., Blavignac, J., Christensen, R. A. G., Kamran, E., Camacho, F., & Barakat, M. (2021) · International Journal of Obesity · doi:10.1038/s41366-021-00831-4 · Cited by 17
Perspectives in weight control in diabetes – SGLT2 inhibitors and GLP-1–glucagon dual agonism
Iqbal, N., Ambery, P., Logue, J., Mallappa, A., & Sjöström, C. D. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110669 · Cited by 14
Pharmacologic Approaches to Weight Management: Recent Gains and Shortfalls in Combating Obesity
Saunders, K. H., Kumar, R. B., Igel, L. I., & Aronne, L. J. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0589-y · Cited by 13
Addressing Obesity in Clinical Gynecology Practice
Kahan, S. I., & Winston, G. J. (2018) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000334 · Cited by 14
Anker, S. D., Ji, L., Kindel, T., Coats, A. J. S., Ojji, D., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2025) · Global Cardiology · doi:10.4081/cardio.2025.86 · Cited by 17
Update on Pediatric Anti-obesity Medications—Current Landscape and Approach to Prescribing
Ahn, Y. J., Maya, J., & Singhal, V. (2024) · Current Obesity Reports · doi:10.1007/s13679-024-00566-z · Cited by 12
Moreira, R. O., Valério, C. M., Hohl, A., Moulin, C., Moura, F., Trujilho, F. R., Gerchman, F., Corrêa, L. L., Mancini, M. C., de Melo, M. E., et al. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2024-0422 · Cited by 29
“The clinical development program for the N/B combination was named Contrave Obesity Research (COR) and involved two phase 2 studies and four phase 3 studies: COR-I (148), COR-II (149), COR-BMOD (Behavior Modification) (150), and COR-Diabetes (151).”
InfluentialObesity management for cardiovascular disease prevention
Hritani, R., Rifai, M. A., Mehta, A., & German, C. A. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100069 · Cited by 15
“0.3%, respectively with p 0.001) [39].”
BackgroundInfluentialStumpf, M. A. M., Cercato, C., de Melo, M. E., Santos, R. D., & Mancini, M. C. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad280 · Cited by 12
Type 2 Diabetes Treatment in the Patient with Obesity
Malin, S. K., & Kashyap, S. R. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2016.04.007 · Cited by 15
Treating obesity in patients with cardiovascular disease: the pharmacotherapeutic options
Andrew, C. A., Saunders, K. H., Shukla, A. P., & Aronne, L. J. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1561867 · Cited by 11
Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity
C, K. A. C. M. V. R. L. J. K. A. G. A. A. A. B. B. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005729 · Cited by 36
Weight Loss‐Associated Remodeling of Adipose Tissue Immunometabolism
Basso, P. J., Schcolnik‐Cabrera, A., Zhu, M., Strachan, E. R., Clemente‐Casares, X., & Tsai, S. J. (2025) · Obesity Reviews · doi:10.1111/obr.13975 · Cited by 14
The Genetic Blueprint of Obesity: From Pathogenesis to Novel Therapies
Tonin, G., Eržen, S., Mlinarič, Z., Jurišić‐Eržen, D., Horvat, S., Kunej, T., & Klen, J. (2025) · Obesity Reviews · doi:10.1111/obr.13978 · Cited by 17
Dahlberg, S., Chang, E. T., Weiss, S. R., Dopart, P. J., Gould, E. M., & Ritchey, M. E. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s381652 · Cited by 17
“For the outcome hypertension, one naltrexone/bupropion ER study (Hollander et al, 2013) evaluated naltrexone (32 mg/day)/bupropion (360mg/day) treated individuals against placebo treated individuals.”
BackgroundPractical strategies to manage obesity in type 2 diabetes
Rodbard, H. W., Barnard-Kelly, K. D., Pfeiffer, A. F. H., Mauersberger, C., Schnell, O., & Giorgino, F. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15556 · Cited by 10
Gamitaeeumjowee-Tang for weight loss in diabetic patients: A retrospective chart review
Lee, A., Lee, D.-Y., Kim, M.-J., Lee, H.-S., Choi, K.-H., Lim, Y.-W., Lim, Y.-W., & Park, Y.-B. (2021) · 대한한의학회지 · doi:10.13048/jkm.21004 · Cited by 15
An update on pharmacotherapeutic strategies for obesity
Tchang, B. G., Tarazi, M. S., Aras, M., & Shukla, A. P. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1888927 · Cited by 12
Olszanecka‐Glinianowicz, M., Dudek, D., Filipiak, K. J., Krzystanek, M., Markuszewski, L., Ruchała, M. A., & Tomiak, E. (2020) · Arterial Hypertension · doi:10.5603/ah.a2020.0019 · Cited by 10
Zhang, L., Liu, Z., Liao, S., He, H., & Zhang, M. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03160-7 · Cited by 11
Obesity Education Strategies for Cancer Prevention in Women’s Health
Liu, L., Segura, A., & Hagemann, A. R. (2015) · Current Obstetrics and Gynecology Reports · doi:10.1007/s13669-015-0129-8 · Cited by 9
Medications Available for Weight Reduction in Elective Total Joint Arthroplasty
Amanatullah, D. F., Ohanisian, L. L., & Bailony, M. R. (2020) · JBJS Reviews · doi:10.2106/jbjs.rvw.19.00123 · Cited by 10
Lin, C., Cai, X., Yang, W., Lv, F., Nie, L., & Ji, L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.541699 · Cited by 10
“We also screen for agents which can reduce body weight without obvious glycemic control, including orlistat (37–41), Lorcaserin (42), Naltrexone Sustained-Release/Bupropion Sustained-Release (43).”
BackgroundOld and new anti-obesity drugs
Dodangeh, S., & Hasani‐Ranjbar, S. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01512-5 · Cited by 8
“Contrave was evaluated in four randomized, double-blind, placebo-controlled, phase III trials with study durations of 56 weeks: Contrave Obesity Research-I(COR-I) [31], COR-II [32], COR-BMOD [33], and COR diabetes [34]”
Efficacy of Oral Medication in Weight Loss Management: A Systematic Review and Network Meta-Analysis
Benedictus, B., Pratama, V. K. P., Purnomo, C. W., Tan, K., & Febrinasari, R. P. (2025) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.12.013 · Cited by 9
Steenackers, N., Toumassian, J., Deleus, E., Mertens, A. C., Lannoo, M., Pazmiño, S., van Laar, A. D. E., der Schueren, B. V., & Vangoitsenhoven, R. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1569468 · Cited by 21
Obesity: assessment and treatment across the care continuum
Kushner, R. F., & Marla Shapiro, C. M. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2521433 · Cited by 14
la Rosa, A. D., Ghusn, W., Sacoto, D., Campos, A., Cifuentes, L., Feris, F., Busebee, B. T., Calderón, G., Acosta, A. J., & Hurtado, M. D. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100046 · Cited by 8
Consensus on pharmacological treatment of obesity in Latin America
Cappelletti, A. M., Montero, A. V., Cercato, C., Ossman, J. J. D., Vasquez, P. E. F., García, J. E. G., Mancillas‐Adame, L. G., Manrique, H. A., Monterroso, F. D. M. R., Segarra, P., et al. (2023) · Obesity Reviews · doi:10.1111/obr.13683 · Cited by 10
Cutting-Edge Approaches to Obesity Management: The Latest Pharmacological Options
Schmitz, S. H., Saunders, K. H., & Aronne, L. J. (2025) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.09.003 · Cited by 12
Update on drug safety evaluation of naltrexone/bupropion for the treatment of obesity
Bello, N. T. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1618268 · Cited by 13
Metabolic Influences of Commonly used Antidepressants on Blood Glucose Homeostasis
Meng, H., Ji, L., & Zhang, X. (2019) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.498 · Cited by 8
Cardiovascular effects of anti-obesity medications: the perils and promise
Zheng, H. (2025) · Cardiology Plus · doi:10.1097/cp9.0000000000000114 · Cited by 7
Treating obesity in patients with depression: a narrative review and treatment recommendation
Kushner, P. R., Kahan, S. I., & McIntyre, R. S. (2025) · Postgraduate Medicine · doi:10.1080/00325481.2025.2478812 · Cited by 10
“Notably, patients with diabetes receiving NB-ER also showed improvements in depression scores, demonstrating that the effects of NB-ER on depression extend to patients with concomitant diabetes and obesity [150].”
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
Weight loss to disrupt type 2 diabetes
Alsaqaaby, M. S., & le Roux, C. W. (2023) · Diabetology International · doi:10.1007/s13340-023-00626-0 · Cited by 8
Phipps, D., & Helton, M. R. (2023) · Springer eBooks · doi:10.1007/978-3-031-29171-5_2 · Cited by 12
Antiobesity drugs in the management of type 2 diabetes: A shift in thinking?
Burguera, B. G., Ali, K. F., & Brito, J. P. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84.s1.05 · Cited by 10
Cardiometabolic Effects of Anti-obesity Pharmacotherapy
Crawford, A. R., Alamuddin, N., & Amaro, A. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0719-9 · Cited by 10
Metadata
- Authors
- Hollander, P., Gupta, A. K., Plodkowski, R., Greenway, F., Bays, H., Burns, C., Klassen, P., Fujioka, K., & for the COR-Diabetes Study Group
- Affiliations
- Baylor University Medical Center (US)
- Pennington Biomedical Research Center (US)
- Scripps Clinic (US)
- Louisville Metabolic and Atherosclerosis Research Center (US)
- Orexigen Therapeutics (United States) (US)
- Corresponding author
- Hollander, Priscilla
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-11-13
- Volume
- 36
- Issue
- 12
- Pages
- 4022-4029
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3836105
- OpenAlex
- W2020982355
- Cited by
- 501
- References
- 39
- Citations by year
- 2026: 29 · 2025: 50 · 2024: 56 · 2023: 51 · 2022: 35 · 2021: 47 · 2020: 34 · 2019: 27 · 2018: 34 · 2017: 40 · 2016: 42 · 2015: 43 · 2014: 12 · 2013: 1
- FWCI
- 23.98
- Type
- journal article
- Language
- en
- Update notices
- correction (2014-02-01)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- naltrexone/bupropion, combination therapy, type 2 diabetes, obesity, overweight, weight loss, glycemic control, HbA1c, triglycerides, HDL cholesterol, nausea, constipation, vomiting, antidepressant side effects, cardiovascular risk factors, lifestyle intervention, drug safety, drug efficacy, suicidal ideation, hypoglycemia
- MeSH terms
- Adolescent, Adult, Aged, Blood Glucose, Body Weight, Delayed-Action Preparations, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Naltrexone, Narcotic Antagonists, Obesity, Retrospective Studies, Risk Factors, Weight Loss, Bupropion, Treatment Outcome, Antidepressive Agents, Second-Generation, Overweight, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.